Low-Dose Naltrexone Young Adult (18-29) Monitoring

How LDN differs from approved naltrexone

Approved naltrexone is the 50 mg tablet, indicated for alcohol dependence and blockade of opioid effects, and Vivitrol 380 mg monthly injection [1][2]. LDN is an off-label, compounded use. Evidence on LDN safety in pregnancy and in liver or kidney impairment is sparse [3]. A 2026 review of 105 LDN studies, 15 of them randomized trials, concluded that current evidence does not support routine clinical use [3].

The opioid contraindication

Naltrexone is contraindicated in people receiving opioid analgesics, people currently dependent on opioids including methadone or buprenorphine, people in acute opioid withdrawal, and anyone who has failed the naloxone challenge test or has a positive urine screen for opioids [1][2]. The contraindication for people receiving opioid analgesics is written without any dose exception [1]. Naltrexone can also block opioid-containing cough, cold and antidiarrheal medicines [1].

Starting naltrexone too soon after opioid use can precipitate withdrawal, which may be severe enough to require hospitalization. In the tablet label, symptoms usually began within five minutes and lasted up to 48 hours, and postmarketing cases required hospital admission [1]. The labels recommend an opioid-free interval of at least 7 to 10 days; the tablet label says people coming from buprenorphine or methadone may be vulnerable to precipitated withdrawal for as long as two weeks [1][2].

Liver, side effects and mood

Hepatitis and clinically significant liver dysfunction were reported during development and after marketing, and the Vivitrol label says to discontinue for symptoms or signs of acute hepatitis [1][2]. The tablet label ties injury to dose: at up to 300 mg a day, five times the recommended dose, hepatocellular injury occurred in a substantial proportion of patients [1]. In short-term alcohol trials of Vivitrol, AST elevations occurred in 1.5% on Vivitrol and 1.5% on oral naltrexone versus 0.9% on placebo [2].

LDN trials report mostly mild, transient effects, most often insomnia, vivid dreams, nausea and dizziness [3]. A meta-analysis of four randomized fibromyalgia trials in 222 patients found more vivid dreams and nausea than placebo but no significant difference in serious adverse events [4]. Depression, suicidal ideation and suicide attempts have been reported after marketing; the tablet label says no causal relationship has been demonstrated and that alcohol- and opioid-dependent patients should be monitored [1].

Pregnancy

The tablet label states there are no adequate and well-controlled studies in pregnant women. Animal studies showed early fetal loss at high oral doses, with no malformations up to 200 mg/kg/day during organogenesis [1].

Evidence for LDN in fibromyalgia

LDN's benefit remains uncertain. A small trial of 31 women reported a 28.8% pain reduction on 4.5 mg versus 18.0% on placebo [6]. Later placebo-controlled trials were negative on their primary outcomes: median FIQR difference -1.65 in 58 patients (P=0.3) [7]; between-group pain difference -0.34 points in 99 women (95% CI -0.95 to 0.27) [8]; pain change -0.33 on LDN versus -0.64 on placebo in 98 women at 3 months [9]. A meta-analysis of four trials found pain 0.86 points lower with LDN but no FIQR difference [4].

The compounded product

No FDA-approved low-dose naltrexone product exists; LDN is made by compounding pharmacies [3][10]. FDA states that compounded drugs are not FDA-approved and that it does not verify their safety, effectiveness or quality before they are marketed [10]. Naltrexone is not named on FDA's list of bulk drug substances that raise significant safety risks [11]. HealthRX.com offers low-dose naltrexone as a compounded prescription.